Some of the world's largest hedge funds are hiring doctors, scientists and analysts to give them expert insight into the ...

Bristol Myers Squibb Co. closed $2.39 below its 52-week high ($61.08), which the company reached on November 11th.

Bristol-Myers Squibb can probably continue to grow for a long time. Its dividend looks to be sustainable at the moment. But ...

Artificial intelligence is changing the way companies do business — helping programmers write code and fielding customer ...

Bristol Myers Squibb has enlisted three-year-old Massachusetts biotech AI Proteins to use its artificial intelligence-driven ...

We recently published a list of 10 Stocks That Are Close To Becoming Dividend Aristocrats. In this article, we are going to ...

Bristol Myers Squibb became the latest large drugmaker to sue the federal government over a plan to change how it doles out ...

The moves will affect more than 300 employees across both companies as both firms look to drive growth in the long term.

Keros’ elritercept has shown promising efficacy signals in myelofibrosis and myelodysplastic syndromes and could pose a ...

It's been a challenging past few years for Bristol Myers Squibb (NYSE: BMY). The company's financial results dipped following ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...